Actively Recruiting
Comparative Study Between Endocan and Copeptin Serum Levels in Preterm Neonates With Respiratory Distress Syndrome
Led by Tanta University · Updated on 2025-09-04
40
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are investigating and comparing the levels of serum endocan and serum copeptin in preterm newborns diagnosed with respiratory distress syndrome (RDS). This study aims to understand how these levels on the first day of life relate to the severity of respiratory distress. Respiratory distress in preterm infants is a significant challenge due to its high risks and impact on families and healthcare. The study involves measuring serum endocan and serum copeptin using enzyme-linked immunosorbent assay (ELISA) tests on the first day of life. Participants include preterm neonates grouped by gestational age: between 28 and 34 weeks and between 34 and 36 weeks. These measurements will help compare the two biomarkers' levels and their association with RDS severity. During the study, blood samples will be taken from the neonates on the first day of life to assess serum endocan and copeptin levels. The researchers will also monitor copeptin levels again on the fifth day of life. The main focus is to predict the severity of respiratory distress syndrome and possible mortality outcomes. The participation period covers the first few days after birth with specific biomarker assessments to support clinical understanding.
CONDITIONS
Brief Title
Endocan and Copeptin Serum Levels in Preterm Neonates With Respiratory Distress Syndrome
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Prematurity
- Gestational age between 28 and 36 weeks
- Diagnosis of respiratory distress syndrome
You will not qualify if you...
- Intrauterine growth restriction (IUGR)
- Hypoxic ischemic encephalopathy
- Multiple congenital anomalies
- Chromosomal abnormalities
- Gestational age less than 28 weeks
- Maternal history of chorioamnionitis (early sepsis)
- Infant of diabetic mother
- Prelabor rupture of membranes (PROM) longer than 2 hours
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - First 5 days of life
Participants have blood samples collected to measure serum endocan and copeptin levels.
1 visit on the first day of life and 1 visit on the fifth day of life
Trial Site Locations
Total: 1 location
1
Tanta University
Tanta, El-Gharbia, Egypt, 31527
Actively Recruiting
Research Team
A
Asmaa M Elmesiry, MD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here